In June, the American Medical Association (AMA) House of Delegates convened in Chicago, Illinois, to deliberate and establish critical policy positions that will shape the landscape of American healthcare for years to come. Representing the specialized interests of the endocrine community, the Endocrine Society dispatched a delegation comprising Naykky Singh Ospina, MD, Amanda Bell, MD, and Daniel Spratt, MD, to advocate for legislative and policy changes essential to the practice of endocrinology and the well-being of patients nationwide. This biennial gathering serves as a cornerstone of medical democracy, where the "House of Medicine" debates the most pressing clinical, ethical, and economic challenges facing the profession. During the multi-day session, the Endocrine Society’s representatives focused their efforts on two primary pillars: achieving insurance parity for comprehensive obesity treatment and advancing critical initiatives in women’s health.
The Legislative Role of the AMA House of Delegates
The AMA House of Delegates (HOD) is the principal legislative and policy-making body of the American Medical Association, representing nearly every sector of the medical profession. Meeting twice annually—once in June for the Annual Meeting and again in November for the Interim Meeting—the HOD is composed of delegates from state medical associations, national medical specialty societies, and professional interest groups. Its primary function is to consider resolutions—formal proposals for change—that, if adopted, become official AMA policy. These policies often serve as the basis for the AMA’s federal and state advocacy efforts, influencing everything from Medicare reimbursement rates to public health legislation in the United States Congress.
The June meeting in Chicago provided a vital platform for the Endocrine Society to engage with the broader medical community. By participating in the HOD, the Society ensures that the voices of hormone specialists are heard in broader discussions regarding patient care. The presence of Dr. Singh Ospina, Dr. Bell, and Dr. Spratt was instrumental in navigating the complex committee structures and testimony sessions where the merits of various resolutions are debated before reaching the floor for a final vote.
Prioritizing Obesity Care as a Chronic Disease
A central focus for the Endocrine Society during the Chicago meeting was the advancement of resolutions focused on the treatment of obesity. For over a decade, the AMA has recognized obesity as a chronic disease requiring a range of medical interventions. However, clinical practice has frequently been hindered by a lack of comprehensive insurance coverage, leaving millions of patients without access to evidence-based treatments.
The Endocrine Society co-sponsored a landmark resolution addressing parity in access to obesity care. This resolution advocated for insurance coverage parity across three critical modalities: bariatric surgery, pharmacotherapy (including anti-obesity medications), and intensive behavioral therapy. The push for parity is rooted in the recognition that obesity is a complex, multifactorial disease that cannot always be managed through lifestyle modifications alone.
Supporting data highlights the urgency of this advocacy. According to the Centers for Disease Control and Prevention (CDC), the prevalence of obesity in the United States reached approximately 41.9% between 2017 and 2020. Despite this, insurance coverage remains fragmented. Many employer-sponsored plans and government programs like Medicare currently exclude or severely limit coverage for newer weight-loss medications, such as GLP-1 receptor agonists, despite their proven efficacy in reducing cardiovascular risks and managing weight. By advocating for parity, the Endocrine Society aims to remove the financial barriers that prevent patients from receiving the gold standard of care.
Addressing the Economic and Clinical Gaps in Obesity Treatment
The advocacy efforts in Chicago were bolstered by a growing body of evidence suggesting that treating obesity proactively results in significant long-term savings for the healthcare system. Untreated obesity is a primary driver of comorbid conditions, including Type 2 diabetes, hypertension, non-alcoholic fatty liver disease (NAFLD), and various forms of cancer.
Analysis presented during the policy discussions suggested that by mandating insurance parity, the medical community could shift the focus from reactive care—treating the complications of obesity—to proactive management. The Endocrine Society’s delegates emphasized that obesity treatment should be viewed with the same clinical necessity as treatments for heart disease or asthma. The resolution supported by the Society specifically calls for an end to the "carve-outs" in insurance policies that allow payers to deny coverage for obesity-related interventions while covering treatments for the secondary diseases those very interventions could prevent.
Advancing Women’s Health and Reproductive Care
Beyond obesity, the Endocrine Society played a significant role in supporting resolutions dedicated to women’s health. Endocrinology is deeply intertwined with women’s health, encompassing reproductive health, menopause management, polycystic ovary syndrome (PCOS), and thyroid disorders, which disproportionately affect women.
The Society’s delegates supported initiatives aimed at improving access to specialized care and addressing the unique hormonal health challenges faced by women across their lifespan. In the current legislative climate, where reproductive health access is a subject of intense national debate, the Endocrine Society’s involvement in the AMA HOD ensures that medical policy remains grounded in scientific evidence and patient autonomy.
The advocacy in Chicago also touched upon the necessity of clinical research that includes diverse female populations. Historically, medical research has faced a "gender gap," where treatments were primarily tested on male subjects, leading to a lack of data on how certain drugs or therapies affect the female endocrine system. The Endocrine Society’s support for women’s health resolutions at the AMA level reinforces the need for equitable research and clinical guidelines that reflect the biological realities of all patients.
Chronology of the AMA Annual Meeting
The process of establishing these policies follows a rigorous timeline. The June meeting began with the opening of the House of Delegates, followed by several days of "Reference Committee" hearings. During these hearings, delegates like Dr. Singh Ospina, Dr. Bell, and Dr. Spratt provided expert testimony on behalf of the Endocrine Society. This stage is crucial, as it allows specialists to explain the clinical nuances of a resolution to delegates from other fields, such as surgery, pediatrics, or emergency medicine.
Following the testimony, the Reference Committees met in executive sessions to draft recommendations for the full House. In the final days of the meeting, the House of Delegates debated these recommendations on the floor. The adoption of the resolution on obesity care parity marked a significant victory for the Endocrine Society, signaling a unified front within the AMA to challenge restrictive insurance practices.
Broader Implications for the Healthcare Industry
The policies adopted at the June AMA meeting carry significant weight in the broader healthcare industry. When the AMA takes a formal stance on an issue like insurance parity for obesity, it provides a powerful tool for lobbyists and advocacy groups working in Washington, D.C., and state capitals.
For the pharmaceutical industry, the AMA’s support for pharmacotherapy parity may accelerate the inclusion of anti-obesity medications in standard formularies. For hospital systems, the push for surgical parity could lead to more robust bariatric programs. Most importantly, for patients, these policy shifts represent a move toward a more equitable system where the treatment of a chronic disease is determined by medical necessity rather than the specific terms of an insurance contract.
Furthermore, the Endocrine Society’s proactive stance at the AMA meeting reflects a broader trend of specialty societies taking a leading role in national health policy. By collaborating with other organizations—such as the American Society for Metabolic and Bariatric Surgery (ASMBS) and the Obesity Society—the Endocrine Society has helped build a coalition that is difficult for policymakers to ignore.
Official Responses and Stakeholder Perspectives
While the AMA does not release the specific voting tallies of the HOD, the general consensus following the June meeting was one of progress. Leaders within the Endocrine Society expressed gratitude to their delegates for their tireless work in Chicago. The Society noted that the successful advocacy for obesity and women’s health resolutions is a testament to the power of physician leadership.
Stakeholders in the patient advocacy community have also reacted positively to the AMA’s updated positions. Groups representing individuals with obesity have long argued that the lack of insurance coverage is a form of medical discrimination. The AMA’s support for parity is seen as a major step toward de-stigmatizing obesity and ensuring that the healthcare system treats it with the same urgency as any other life-threatening condition.
Looking Ahead: The Future of Endocrine Advocacy
The conclusion of the June meeting marks the beginning of the implementation phase. The Endocrine Society, alongside the AMA, will now look toward the fall and the upcoming legislative sessions to translate these policy positions into law. A key target remains the "Treat and Prevent Obesity Act" (TPOA) in Congress, which seeks to expand Medicare coverage to include anti-obesity medications and intensive behavioral therapy. The newly established AMA policies provide the Endocrine Society with additional leverage to urge lawmakers to pass this critical piece of legislation.
As the medical field continues to evolve with the introduction of new therapies and a deeper understanding of hormonal health, the role of the Endocrine Society in the AMA House of Delegates will remain paramount. The efforts of Dr. Singh Ospina, Dr. Bell, and Dr. Spratt in Chicago have laid the groundwork for a more inclusive and effective healthcare system—one that recognizes the complexity of chronic disease and prioritizes the health of women and patients struggling with obesity.
The Endocrine Society remains committed to its mission of advocating for the highest standards of care. By maintaining a strong presence in the AMA’s legislative process, the Society ensures that endocrinologists remain at the forefront of medical policy, driving changes that benefit the profession and the diverse patient populations they serve. The resolutions passed in June are not merely statements of intent; they are a roadmap for the future of American medicine, emphasizing science, equity, and the fundamental right of patients to access evidence-based care.
